Project description:Intervention1: Exercise and Vit D supplement: STUDY PARTICIPANTS WILL BE TAUGHT EXERCISE TO BE CARRIED OUT MINIMUM 2.5 HOURS/ WEEK FOR 12 MONTHS FROM THE TIME OF RECRUITMENT AND WILL BE GIVEN VIT D SUPPLEMENTS OF 60,000 I.U. PER WEEK TO BE CONSUMED ORALLY FOR THE 1ST 4 WEEKS FOLLOWED BY 60,000 I.U. EVERY ALTERNATE WEEK FOR 8 WEEKS
THE EFFECT WILL BE MEASURED USING STANDARDISED INSTRUMENTS FOR COGNITIVE AND NON COGNITIVE FUNCTIONS
Control Intervention1: Standard treatment: It will be prescribed by the treating medical oncologist
Primary outcome(s): I. Primary objectives
a) To assess the cognitive and non cognitive function of participants in experimental group before and after planned intervention
c) To compare the cognitive function of participants in experimental and control group before and after planned intervention
II. Secondary Objectives
a) To assess the non- cognitive function and serum TNF alpha levels of participants in control and study group before and after planned intervention
Timepoint: 0,3,6,9,and 12 months
Project description:To investigate how histone demethylases KDM4B and KDM6B may be involved in osteogenic commitment of mesenchymal stem cells (MSCs), we performed gene expression profiling and comparison on control, KDM4B- and KDM6B-knockdown MSCs at different stages of osteogenic differentiation. Human MSCs infected with scramble shRNAs, shRNAs against KDM4B or KDM6B are treated with BMP4/7 for 0, 4 and 24hrs. Total RNA were extracted from these 9 samples.
Project description:Recent studies have indicated that the histone 3 lysine 27 (H3K27me2/3) demethylase KDM6B (JMJD3) is frequently upregulated in a myriad of blood disorders including myelodysplastic syndrome (MDS), T-cell acute lymphoblastic leukemia (T-ALL), and multiple myeloma (MM) suggesting it may have important functions in the pathogenesis of hematopoietic cancers. Here, we sought to determine the role of Kdm6b in hematopoietic stem cell (HSC) fate decisions under normal and malignant conditions to evaluate its potential as a therapeutic target. We show that loss of Kdm6b leads to a significant reduction in phenotypic and functional HSCs in adult mice, and that Kdm6b is necessary for HSC self-renewal in response to inflammatory, genotoxic and oncogenic stress. Additionally, we show that loss of Kdm6b in HSCs leads to a stress-response gene expression signature in native HSCs that is independent of its demethylase activity. Loss of Kdm6b lead to increased expression of a subset of genes implicated in HSC quiescence (e.g. Fos, Jun, Ier2, Dusp1, Zfp36). Upon inflammatory or replicative stress, HSCs deficient for Kdm6b are not able to efficiently resolve this gene expression program, leading to increased quiescence and a self-renewal block, forcing them to differentiate. These findings show that Kdm6b is necessary for self-renewal of normal and leukemic stem cells, and suggest inhibiting Kdm6b in blood cancers in the presence of proliferative agents may force differentiation and eventual depletion of leukemic stem cells.
Project description:We profiled basal and bicuculline+4-AP inducible mRNA expression in cultured mouse hippocampal neurons with or without viral shRNA mediated knockdown of Kdm6b We harvested mRNA from neurons under four conditions (pLKO vector/treatment control, pLKO vector/3hr bicuculline+4AP, Kdm6b knockdown/treatment control,Kdm6b knockdown/3hr bicuculline+4AP). Libraries were generated and used for RNA sequencing.
Project description:TLS are composed of immune cells, including lymphocytes and myeloid cells, lymphatic and blood endothelial cells, and PDPN+ stromal cells with lymphoid stromal cells (LSC) features called immunofibroblasts. These LSC play a central role in the physiology of secondary lymphoid organs. Recent studies have focused on the heterogeneity of immunofibroblast and their cell of origin, but molecular and epigenetic mechanisms involved in their commitment are still unknown. In this study, we took advantage of the combination of an in vitro model of human ASC commitment to LSC/immunofibroblasts, and an in vivo model of murine TLS induction. We highlighted in both cases an early induction of KDM6B in stromal cells associated with an early epigenetic reprogramming. The KDM6B signature was enriched in sorted pathogenic stroma from patients with autoimmune diseases. Furthermore, using a KDM6 inhibitor, we demonstrated that KDM6B was required for the acquisition of immunofibroblast phenotype and functions, including upregulation of CCL2 production and monocyte recruitment. Overall, our results shed light on epigenetic mechanisms involved in the early commitment, but also immune properties of immunofibroblasts.
Project description:Somatic cells can be reprogrammed to pluripotent stem cells through the addition of just four transcription factors, OCT4, SOX2, KLF4 and c-MYC (OSKM). Although OSKM initiates reprogramming it is clear that extensive epigenetic remodeling is required to complete reprogramming. Critically, OSKM do not directly activate gene expression but instead recruit co-activators and co-repressors that remodel the local chromatin and in some way make the cells permissive for reprogramming. Consequently understanding how epigenetic co-repressors and co-activators are involved in reprogramming is a critical step in understanding the reprogramming process in detail. In this study we explored the role of the lysine-specific demethylase Kdm6b/Jmjd3 and its role in the reprogramming of somatic cells to pluripotent cells.